Abstract library

533 results for "imaging criteria".
#2993 Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1
Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Louis de Mestier
#1334 Early Evaluation of Sunitinib in Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) by CT Imaging: RECIST or Choi Criteria?
Introduction: There is no study to assess RECIST and Choi criteria in evaluating response of advanced GEP-NENs treated with sunitinb.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Yanji Luo
Authors: Luo Y, Chen J, Li Z P, Feng S T, ...
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#1121 Epidemiology and Classification of Gastroenteropancreatic Neuroendocrine Neoplasms Using the WHO 2010 Criteria: A Cohort Study in a Defined Norwegian Population.
Introduction: Incidence figures of gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) still remain uncertain.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Oddvar Sandvik
Keywords: GEP-NEN, epidemiology, WHO
#491 International Survey for the Use of Biomarkers and Molecular Imaging in Neuroendocrine Tumors (NET): What we are Using in Daily Practice
Introduction: Several guidelines have given recommendations for optimal use of biomarkers and molecular imaging. However, those guidelines’ implementation may not be always possible due to local policies or lack of access to several diagnostic studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR CHRISTOS Toumpanakis
#772 Role of Molecular Imaging using Ga-68 Somatostatin-Receptor PET/CT in Predicting Survival after Peptide Receptor Radionuclide Therapy of Neuroendocrine Neoplasms
Introduction: Peptide receptor radionuclide therapy (PRRNT) is valuable for the management of metastasized and/or inoperable neuroendocrine neoplasms (NENs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Harshad Kulkarni
#863 Assessment of Neuroendocrine Tumors' Heterogeneity with Combination of Molecular Imaging Studies
Introduction: Neuroendocrine tumors (NET) are heterogeneous neoplasms. The choice of the appropriate molecular imaging study for assessment of disease extent usually depends on tumor grade.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Roberta E Rossi
#2014 Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study
Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). Targeting the cholecystokinine-2 (CCK-2) receptor with radiolabeled gastrin analogues is a potential approach for radionuclide therapy of MTC.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Christof Rottenburger
#1394 The Difficulties of Response Assessment After Peptide Receptor Radionucleotide Therapy (PRRT): An Unusual Case of Symptomatic Pseudoprogression
Introduction: In previous studies patient symptoms, biochemistry (including chromogranin A) and imaging using RECIST criteria have been used to assess tumour response to PRRT.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Lyle M, Wyld D, Burge M, ...
#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)
Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: PhD Paula Jimenez-Fonseca